BTIG Research Cuts Zevra Therapeutics (NASDAQ:ZVRA) Price Target to $24.00

Posted by Brenda Bartman on Jul 30th, 2026

Zevra Therapeutics (NASDAQ:ZVRA – Free Report) had its price target trimmed by BTIG Research from $27.00 to $24.00 in a report issued on Monday morning, Marketbeat.com reports. The brokerage currently has a buy rating on the stock.

A number of other analysts also recently commented on ZVRA. Weiss Ratings downgraded Zevra Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research note on Friday, May 22nd. Cantor Fitzgerald raised their target price on Zevra Therapeutics from $24.00 to $34.00 and gave the company an “overweight” rating in a research note on Monday, June 8th. Guggenheim lifted their target price on Zevra Therapeutics from $25.00 to $29.00 and gave the stock a “buy” rating in a report on Wednesday, June 10th. UBS Group reiterated a “buy” rating on shares of Zevra Therapeutics in a research report on Wednesday, June 24th. Finally, Citigroup reissued an “outperform” rating on shares of Zevra Therapeutics in a report on Tuesday, June 9th. Nine equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $26.86.

Get Our Latest Stock Analysis on Zevra Therapeutics

Zevra Therapeutics Price Performance

NASDAQ ZVRA opened at $9.78 on Monday. Zevra Therapeutics has a 12 month low of $7.16 and a 12 month high of $15.03. The firm has a market capitalization of $578.19 million, a PE ratio of 4.91 and a beta of 0.85. The company’s 50 day simple moving average is $12.34 and its 200 day simple moving average is $10.50.

Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report) last announced its earnings results on Wednesday, May 6th. The company reported $0.18 EPS for the quarter, topping the consensus estimate of $0.06 by $0.12. The firm had revenue of $36.22 million for the quarter, compared to analysts’ expectations of $31.96 million. Zevra Therapeutics had a return on equity of 51.49% and a net margin of 101.58%. Sell-side analysts anticipate that Zevra Therapeutics will post 0.56 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Zevra Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Gunpowder Capital Management LLC dba Oliver Wealth Management acquired a new position in shares of Zevra Therapeutics in the 4th quarter worth $53,000. Russell Investments Group Ltd. lifted its holdings in shares of Zevra Therapeutics by 235.7% during the third quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock valued at $61,000 after purchasing an additional 4,475 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of Zevra Therapeutics by 617.5% during the second quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock valued at $88,000 after purchasing an additional 8,552 shares during the last quarter. Creative Planning acquired a new position in shares of Zevra Therapeutics in the 2nd quarter valued at $92,000. Finally, Qube Research & Technologies Ltd acquired a new position in shares of Zevra Therapeutics in the 2nd quarter valued at $99,000. Institutional investors and hedge funds own 35.03% of the company’s stock.

About Zevra Therapeutics

(Get Free Report)

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.